Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Lagevrio (molnupiravir)
- vericiguat
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food interactions
vericiguat food
Applies to: vericiguat
ADJUST DOSING INTERVAL: Administration of vericiguat with food reduces its pharmacokinetic variability and increases its exposure. Vericiguat is less soluble at neutral pH than at acidic pH. Administration of vericiguat with a high-fat, high-calorie meal or low-fat, high-carbohydrate meal increased time to reach peak plasma concentration (Tmax) from about 1 hour (fasted) to about 4 hours (fed) and increased vericiguat systemic exposure (AUC) by 19% and peak plasma concentration (Cmax) by 9% for the 5 mg tablet and by 44% (AUC) and 41% (Cmax) for the 10 mg tablet as compared with the fasted state. Concurrent treatment with drugs that increase gastric pH, such as proton pump inhibitors or antacids, decrease vericiguat AUC by about 30%. Co-treatment with drugs that increase gastric pH did not affect vericiguat exposure in patients with heart failure when vericiguat was taken as directed with food.
MANAGEMENT: Administer vericiguat with food to ensure maximal exposure and decrease pharmacokinetic variability.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2021) "Product Information. Verquvo (vericiguat)." Merck & Co., Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Paxlovid
PAXLOVID (nirmatrelvir with ritonavir) is an antiviral medication used to treat COVID-19. Includes ...
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Tyenne
Tyenne is approved to treat adults with moderately to severely active rheumatoid arthritis, Giant ...
Olumiant
Olumiant is used to treat rheumatoid arthritis, alopecia areata (hair loss), and COVID-19. Includes ...
Kineret
Kineret is used to treat the symptoms of moderate to severe rheumatoid arthritis ...
Veklury
Veklury is used to treat COVID-19 in adults and children from birth who weigh at least 3.3 pounds ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.